Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients. / Düring, Signe; Glenthøj, Birte Y; Andersen, Gitte Saltoft; Oranje, Bob.

In: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Vol. 39, No. 13, 12.2014, p. 3000-3008.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Düring, S, Glenthøj, BY, Andersen, GS & Oranje, B 2014, 'Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients', Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, vol. 39, no. 13, pp. 3000-3008. https://doi.org/10.1038/npp.2014.152

APA

Düring, S., Glenthøj, B. Y., Andersen, G. S., & Oranje, B. (2014). Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(13), 3000-3008. https://doi.org/10.1038/npp.2014.152

Vancouver

Düring S, Glenthøj BY, Andersen GS, Oranje B. Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2014 Dec;39(13):3000-3008. https://doi.org/10.1038/npp.2014.152

Author

Düring, Signe ; Glenthøj, Birte Y ; Andersen, Gitte Saltoft ; Oranje, Bob. / Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients. In: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2014 ; Vol. 39, No. 13. pp. 3000-3008.

Bibtex

@article{bafcd67ed658425b9d247e57e0702672,
title = "Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients",
abstract = "It has been suggested that psychophysiological measures of sensory and sensorimotor gating, P50 gating and prepulse inhibition of the startle reflex (PPI), underlie core features of schizophrenia and are linked to dopaminergic pathways in the striatum and prefrontal cortex. In the present study, the effects of a potent D2/D3 receptor antagonist, amisulpride, were investigated on PPI and P50 gating in a large sample of antipsychotic-naive, first-episode patients with schizophrenia. A total of 52 initially antipsychotic-naive, first-episode schizophrenia patients were assessed for their P50 gating, PPI, and habituation/sensitization abilities at baseline and after 2 and 6 weeks of treatment with flexible doses of amisulpride. In addition, 47 matched healthy controls were assessed at baseline and after 6 weeks. At baseline, the patients showed significantly reduced PPI, yet normal levels of P50 gating, habituation, and sensitization. Treatment with amisulpride showed no effects on these measures, either at 2 or 6 weeks of follow-up. This is the first study investigating the effects of monotherapy with a relatively selective dopamine D2/D3 receptor antagonist (amisulpride) on sensory and sensorimotor gating deficits in a longitudinal study of a large group of initially antipsychotic-naive, first-episode patients with schizophrenia. Our finding that amisulpride effectively reduced symptom severity in our patients without reducing their PPI deficits indicates that increased activity of dopamine D2 receptors may be involved in symptomatology of patients with schizophrenia, but not in their sensorimotor gating deficits.",
author = "Signe D{\"u}ring and Glenth{\o}j, {Birte Y} and Andersen, {Gitte Saltoft} and Bob Oranje",
year = "2014",
month = dec,
doi = "10.1038/npp.2014.152",
language = "English",
volume = "39",
pages = "3000--3008",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "nature publishing group",
number = "13",

}

RIS

TY - JOUR

T1 - Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients

AU - Düring, Signe

AU - Glenthøj, Birte Y

AU - Andersen, Gitte Saltoft

AU - Oranje, Bob

PY - 2014/12

Y1 - 2014/12

N2 - It has been suggested that psychophysiological measures of sensory and sensorimotor gating, P50 gating and prepulse inhibition of the startle reflex (PPI), underlie core features of schizophrenia and are linked to dopaminergic pathways in the striatum and prefrontal cortex. In the present study, the effects of a potent D2/D3 receptor antagonist, amisulpride, were investigated on PPI and P50 gating in a large sample of antipsychotic-naive, first-episode patients with schizophrenia. A total of 52 initially antipsychotic-naive, first-episode schizophrenia patients were assessed for their P50 gating, PPI, and habituation/sensitization abilities at baseline and after 2 and 6 weeks of treatment with flexible doses of amisulpride. In addition, 47 matched healthy controls were assessed at baseline and after 6 weeks. At baseline, the patients showed significantly reduced PPI, yet normal levels of P50 gating, habituation, and sensitization. Treatment with amisulpride showed no effects on these measures, either at 2 or 6 weeks of follow-up. This is the first study investigating the effects of monotherapy with a relatively selective dopamine D2/D3 receptor antagonist (amisulpride) on sensory and sensorimotor gating deficits in a longitudinal study of a large group of initially antipsychotic-naive, first-episode patients with schizophrenia. Our finding that amisulpride effectively reduced symptom severity in our patients without reducing their PPI deficits indicates that increased activity of dopamine D2 receptors may be involved in symptomatology of patients with schizophrenia, but not in their sensorimotor gating deficits.

AB - It has been suggested that psychophysiological measures of sensory and sensorimotor gating, P50 gating and prepulse inhibition of the startle reflex (PPI), underlie core features of schizophrenia and are linked to dopaminergic pathways in the striatum and prefrontal cortex. In the present study, the effects of a potent D2/D3 receptor antagonist, amisulpride, were investigated on PPI and P50 gating in a large sample of antipsychotic-naive, first-episode patients with schizophrenia. A total of 52 initially antipsychotic-naive, first-episode schizophrenia patients were assessed for their P50 gating, PPI, and habituation/sensitization abilities at baseline and after 2 and 6 weeks of treatment with flexible doses of amisulpride. In addition, 47 matched healthy controls were assessed at baseline and after 6 weeks. At baseline, the patients showed significantly reduced PPI, yet normal levels of P50 gating, habituation, and sensitization. Treatment with amisulpride showed no effects on these measures, either at 2 or 6 weeks of follow-up. This is the first study investigating the effects of monotherapy with a relatively selective dopamine D2/D3 receptor antagonist (amisulpride) on sensory and sensorimotor gating deficits in a longitudinal study of a large group of initially antipsychotic-naive, first-episode patients with schizophrenia. Our finding that amisulpride effectively reduced symptom severity in our patients without reducing their PPI deficits indicates that increased activity of dopamine D2 receptors may be involved in symptomatology of patients with schizophrenia, but not in their sensorimotor gating deficits.

U2 - 10.1038/npp.2014.152

DO - 10.1038/npp.2014.152

M3 - Journal article

C2 - 24954063

VL - 39

SP - 3000

EP - 3008

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 13

ER -

ID: 138175880